Bristol Myers Squibb shared on LinkedIn:
“Our researchers are investigating the CCR8 immune pathway as part of our work to advance innovative immunotherapy approaches for solid tumors.
By studying how CCR8 functions within the tumor microenvironment, we’re working to better understand new ways to engage the immune system against cancer.
Learn more about the science behind this research.”
Key Takeaways
- CCR8 as a target: CCR8 is found at high levels on regulatory T cells (Tregs) in tumors. These cells can weaken the immune system’s ability to fight cancer.
- Reducing immune suppression: BMS is studying whether targeting CCR8 can remove these suppressive cells and help the immune system respond more effectively to tumors.
- A more targeted approach: The goal is to reduce Tregs inside tumors while preserving those that perform important functions in healthy tissues.
- Antibody-based research: BMS is developing anti-CCR8 antibody approaches that use immune mechanisms such as ADCC and ADCP to eliminate targeted cells.
- Potential combinations: Researchers are also exploring whether this approach could work alongside checkpoint inhibitors and chemotherapy.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company that develops treatments for a range of serious diseases, including cancer, blood disorders, cardiovascular and immune-related conditions. The company invests heavily in research and development, particularly in oncology, where it has played an important role in advancing immunotherapy and treatments that use the immune system to fight cancer.
You may also be interested in:
- Bristol Myers Squibb Supports LungÕ 2026 as Foundational Sponsor
- Can the Tumor’s Own B Cells Reveal the Next Immunotherapy Target?
